The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

Inclusion Criteria:

• Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed
• Participant must have diagnosis of cancer that is advanced or metastatic
• Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy
• If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
• If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding

Exclusion Criteria:

• Participant must not have symptomatic central nervous system malignancy or metastasis
• Participant must not have current hematologic malignancy
• Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
• Participant must not have a serious cardiac condition